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Abstract 
Background: DNA methylation is involved in the regulation of gene expression and phenotypic variation, but the 
inter‑relationship between genetic variation, DNA methylation and gene expression remains poorly understood. 
Here we combine the analysis of genetic variants related to methylation markers (methylation quantitative trait loci: 
mQTLs) and gene expression (expression quantitative trait loci: eQTLs) with methylation markers related to gene 
expression (expression quantitative trait methylation: eQTMs), to provide novel insights into the genetic/epigenetic 
architecture of colocalizing molecular markers.
Results: Normal mucosa from 100 patients with colon cancer and 50 healthy donors included in the Colonomics 
project have been analyzed. Linear models have been used to find mQTLs and eQTMs within 1 Mb of the target gene. 
From 32,446 eQTLs previously detected, we found a total of 6850 SNPs, 114 CpGs and 52 genes interrelated, generat‑
ing 13,987 significant combinations of co‑occurring associations (meQTLs) after Bonferromi correction. Non‑redun‑
dant meQTLs were 54, enriched in genes involved in metabolism of glucose and xenobiotics and immune system. 
SNPs in meQTLs were enriched in regulatory elements (enhancers and promoters) compared to random SNPs within 
1 Mb of genes. Three colorectal cancer GWAS SNPs were related to methylation changes, and four SNPs were related 
to chemerin levels. Bayesian networks have been used to identify putative causal relationships among associated 
SNPs, CpG and gene expression triads. We identified that most of these combinations showed the canonical pathway 
of methylation markers causes gene expression variation (60.1%) or non‑causal relationship between methylation 
and gene expression (33.9%); however, in up to 6% of these combinations, gene expression was causing variation in 
methylation markers.
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Background
Over the past few years, multiple studies have shown that 
variation in germline genetics can modify DNA meth-
ylation levels, and subsequently, affect transcription and 
phenotypic variation [1–4]. These genetic variants are 
called methylation quantitative trait loci (mQTLs), in 
contrast to expression quantitative trait loci (eQTLs) that 
modify gene expression levels. Moreover, CpG sites and 
genes whose methylation and gene expression are corre-
lated are known as expression quantitative trait methyla-
tion (eQTMs) [5].
To date, the extent at which DNA methylation is 
affected by genetic variation in colon tissue, as well as the 
extent of the genetically regulated gene expression that is 
mediated by methylation, remains unclear. Thus, solving 
the relations between genetic variants, methylation levels 
and gene expression levels may provide insight into the 
inter-individual variation of complex traits and diseases.
Although DNA methylation is often considered a 
repressive mark, its relationship with gene expression is 
complex. DNA methylation in promoters and enhanc-
ers is usually associated with transcriptional repression, 
while methylated CpGs located in the gene body are 
often associated with transcriptional activation and can 
also play a role in alternative splicing [6].
In this study, our objectives were to map common 
genetic variation affecting methylation levels (mQTLs) 
and methylation CpGs affecting gene expression levels 
(eQTMs) in healthy colon tissue and to identify causal 
relations between co-localizing mQTLs, eQTMs and 
eQTLs.
We analyzed 100 samples of normal colon tissue, adja-
cent to tumor, from patients with colon cancer and 50 
samples of normal colon mucosae from healthy subjects. 
The analyses were centered in the group of samples that 
combined healthy mucosa donors and adjacent to tumor 
mucosa. We will call this group of samples Normal. 
Other exploratory analysis with Tumors were performed, 
and these were compared to their paired Adjacent nor-
mal samples only.
The samples of this study have been previously used 
to identify eQTLs [7] and also to profile DNA methyla-
tion which showed that DNA methylation in normal 
tissue of cancer patients was very similar to that of sub-
jects without cancer [8]. In this study, we have assessed 
mQTLs and eQTMs and identified co-localizing tri-
ads of genetic variants, methylation sites and genes 
(meQTLs) (Fig. 1 and Additional File 1: Figure 1). Then 
we have classified these triads into different putative 
causal models using Bayesian network analysis (Fig. 2) 
and provided functional annotation of genetic variants 
associated with colon-related traits and diseases, such 
as colon cancer.
Results
Relationship between methylation and genetic variants 
(mQTLs) in colon tissue
We analyzed the possible association within 1  MB of 
211,268 variable CpGs with 6,568,592 SNPs that passed 
quality control filters and detected 439,043 significant 
mQTLs (p < 4.9e−11). These involved 6713 CpGs (3.2%) 
and 246,758 SNPs (3.8%). The median distance between 
CpG and SNP was 47  Kb with a mean of 90  Kb and a 
standard deviation of 127 Kb. Since both nearby SNPs 
and CpGs are highly correlated, we identified 4524 and 
8064 blocks of non-correlated cis-CpGs and cis-SNPs, 
respectively, and with these blocks we obtained a total 
of 8195 independent mQTLs (Table  1 and Additional 
File 2: Data 1).
Number of mQTLs, eQTLs, eQTMs and meQTLs. 
For each quantitative trait type, the number of genes, 
SNPs, CpGs, the number of independent quantita-
tive traits (see methods) and the number of SNP and 
CpG blocks (elements in cis with r2 < 0.3, see meth-
ods). Normal corresponds to the group of samples 
that combines normal samples from healthy individuals 
(Healthy, n = 37) and normal mucosa adjacent to tumor 
(Adjacent, n = 95) from patients with cancer. Tumor 
corresponds to methylation analyzed in tumor tissue 
(n = 95).
Additional File 3: Table  1 shows these global num-
bers by chromosome. We found an enrichment of non-
correlated mQTLs in chromosome 6, possibly related 
to the human leukocyte antigen (HLA) hypervariable 
region. The distribution of mQTLs was similar to other 
variable CpGs regarding the distribution of median 
methylation levels (Fig. 3) and location in reference to 
genes (Fig.  4) and in reference to CpG island context 
(Additional File 4: Fig. 2).
Conclusions: In this study we provided a characterization of the regulation between genetic variants and inter‑
dependent methylation markers and gene expression in a set of 150 healthy colon tissue samples. This is an impor‑
tant finding for the understanding of molecular susceptibility on colon‑related complex diseases.
Keywords: DNA methylation, Genetics, Gene expression, mQTLs, eQTLs, eQTMs, Genetic and epigenetic control, 
Epigenetic regulation
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Relationship between methylation and gene expression 
(eQTMs) in colon tissue
Next, we found 557 eQTMs in normal colon tissues 
involving the expression of 158 genes (1.1% of the 14,654 
genes) and 482 CpGs (0.2% of the variable CpGs). The 
median distance between the gene TSS and the CpGs was 
168 Kb with a mean of 131 Kb and a standard deviation 
of 254 Kb. From these, we found 155 blocks of non-cor-
related cis- CpGs and 165 independent eQTMs (Table 1 
and Additional File 5: Data 2). Additional File 3: Table 1 
shows these global numbers by chromosome.
Fig. 1 Scheme of the performed analysis. SNPs filt: Only SNPs in autosomal chromosomes and with a MAF between 0.05 and 0.95 have been 
considered. Duplicated SNPs and SNPs with more than 10% of missing values have been removed. CpGs filt: SNPs CpGs or CpGs with missing 
values have been removed. Only CpGs in autosomal chromosomes have been included. CpGs with a standard deviation greater than 0.05 have 
been filtered in. Genes filt: Only genes in autosomal chromosomes and with a standard deviation greater than 0.05 have been considered. All the 
analysis has been adjusted by sex, age and site and the maximum distance between elements was 1 Mb
Fig. 2 Causal relationship models of the 12,720 meQTLs in normal tissues
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The CpGs involved in eQTMs showed a lower propor-
tion of high methylation levels (Fig. 3A, C). The distribu-
tion of CpGs in eQTMs across the different regions of the 
gene context was very different if we looked at the near-
est or at the target gene (Fig.  4C, D). When we looked 
at the nearest gene the proportion of promoter regions 
was very high (46.9%), while when we looked at the tar-
get gene, the proportion of promoter regions was very 
low (14.3%), most of the CpGs being outside the corre-
lated gene (59.7%). The distribution regarding CpG island 
context, Additional File 4: Fig. 2C, is very similar to the 
distribution in variable CpGs and in mQTLs.
There were slightly more eQTMs with a negative cor-
relation between gene expression levels and CpG meth-
ylation levels (65.7%), and, as expected, the CpGs with 
a negative correlation were overrepresented in those 
CpGs that are inside the promoter of the associated gene 
(90.1%) and in the gene body (84.5%) (Fig. 5A).
Co‑occurring triads of associated genetic variants, 
methylation sites and gene expression levels
We had previously identified 32,446 eQTLs [7] (Table 1). 
We have now found that these eQTLs include 650 blocks 
of non-correlated cis-SNPs and 658 independent eQTLs 
(Additional File 5: Data 3).
We found 13,987 meQTLs, that is, triads of CpG, SNP 
and gene co-correlated in pairs of mQTLs, eQTMs and 
eQTLs. This involved 6850 unique SNPs, 114 unique CpGs 
and 52 unique genes; however, when linkage disequilibrium 
and correlation among neighbor CpGs were taken into 
account, there were only 54 and 51 independent blocks of 
cis-SNPs and cis-CpGs, respectively, with 54 independent 
meQTLs (Table 1). Additional File 3: Table 1 shows these 
global numbers by chromosome.
The distribution of the 114 CpGs involved in meQTLs 
showed less methylated CpGs compared with the rest of 
the groups (Fig. 3D). The proportion of CpGs in promot-
ers (47.4%) was increased a little in comparison with the 
proportion in eQTMs, both, if we associated the CpG 
with the nearest gene (Fig.  4C, E) and if we associated 
the CpG with the significant correlated gene in eQTMs 
(Fig.  4D, F). The distribution of CpGs regarding CpG 
island context is very similar in all the groups (Additional 
File 4: Fig. 2).
Figure  5B shows the distribution of the correlation 
of 13,987 eQTMs in meQTLs by gene region context. 
58.9% of the CpGs in meQTLs were negatively corre-
lated with the expression of the gene. CpGs that had 
Table 1 Number of significant associations identified
Normal (n = 132) Adjacent (n = 95) Tumor (n = 95)
mQTLs 439,043 227,934 56,666
independent mQTLs 8195 4229 840
CpGs 6713 4167 850
CpGs blocks 4524 2845 645
SNPs 246,758 141,207 38,751
SNPs blocks 8064 4138 840
eQTMs 557 290 1732
independent eQTMs 165 78 490
Genes 158 78 487
CpGs 482 253 1563
CpGs blocks 155 75 466
eQTLs 32,446 17,274 8530
independent eQTLs 658 279 82
Genes 374 220 80
SNPs 31,482 17,070 8395
SNPs blocks 650 274 79
meQTLs 13,987 5517 1926
independent meQTLs 54 19 6
Genes 52 19 6
CpGs 114 45 16
CpGs blocks 51 19 6
SNPs 6850 2720 1231
SNPs blocks 54 19 6
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a positive correlation were mainly located outside 
the gene region. However, if we analyzed these same 
results but with the 119 unique eQTMs in meQTLs, 
78.2% of the CpGs were negatively correlated with the 
gene and all the groups regarding gene region context 
showed a negative median correlation (Fig. 5C).
Enrichment analyses of genes and SNPs in triads of genetic 
variants, methylation and gene expression
From the 6850 unique SNPs identified in meQTLs, only 
718 (12%) mapped to regions associated with regulatory 
elements, specifically promoters and enhancers, in colonic 
mucosa, as indicated by predicted chromatin states and 
specific histone marks. Remarkably, compared to a subset 
of randomly sampled SNPs within 1 Mb of gene TSS, we 
found a significantly enrichment in SNPs mapping to these 
regulatory elements specially in those associated with pro-
moters (Table 2 and Additional File 7: Fig. 3). As expected, 
these SNPs were also enriched in eQTLs.
Fisher exact test was used to compare, for each anno-
tation in haploReg database, the proportion of SNPs in 
eQTLs, mQTLs and meQTLs with a random sample of 
cis-SNPs. Bonferroni adjusted p-values were calculated 
for chromatin states and histone marks separately.
Additionally, meQTLs were underrepresented 
among genetic conserved regions as indicated by 
GERP and SiPhy algorithms (p-value = 8.6e−21 and 
p-value = 4.4e−05, respectively) (Table 2).
The 52 genes found in meQTLs were mainly enriched 
in two groups of pathways, one related with metabo-
lism of glucose and xenobiotics and other related with 
Fig. 3 Methylation distribution in Normal tissues. Distribution of methylation median of A 211,268 variable CpGs, B 6713 CpGs in mQTLs, C 482 
CpGs in eQTMs and D 114 CpGs in meQTLs
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immune system through HLA genes (Additional File 8: 
Table 2).
A total of  64 SNPs involved in meQTLs (1% of 6850) 
were found associated with 48 traits from the GWAS 
(Table  3). It is interesting to note than all SNPs associ-
ated with circulating chemerin levels were statistically 
significant. From the 116 SNPs reported to be associated 
with colorectal cancer, three were identified as meQTLs: 
rs9271770, in cis with HLA-DRB5 gene, within the 
6p21.33 major histocompatibility region and associated 
with cg00119778; cg07984380 and cg15982117 CpGs; 
rs3087967 in the body of c11orf52 and nearby rs3802842, 
an intronic variant of COLCA1 and COLCA2 in 11q23.1, 
were associated with the same CpG cg23091777.
First column indicates the number of SNPs in each trait 
of the GWAS catalog, second to fourth columns indicate 
the SNPs in meQTLs found in each trait for Normal, 
Adjacent and Tumor groups, respectively. In parentheses, 
the percentage of SNPs in meQTLs that are in the list of 
SNPs associated to each trait.
Putative causal relationships between methylation 
patterns, gene expression and their associated genetic 
variant
To study the putative causal relationship between geno-
types, methylation and expression levels, we used Bayes-
ian networks analysis to identify direct and mediated 
effects. We studied each of the 13,987 meQTLs triads and 
classified them into different models of causal relation-
ships (Fig.  2). The most frequent model involved genet-
ics (G) having a direct (putative causal) effect on gene 
expression (E) and at the same time, having an indirect 
effect on E through methylation levels (Me) (GMeE&GE 
model; 6374 meQTLs; 45.6%). As example, in Fig. 6A, the 
SNP rs9981445 had a direct effect on both cg27244972 
CpG methylation and YBEY gene expression but, at the 
same time, the methylation of the CpG was also directly 
associated with gene expression of YBEY.
The following most frequent model consisted in a 
causal effect of G on both Me and E, with no relation 
between methylation and gene expression, indicating 
a passive role of DNA methylation (GE&GMe model; 
4740 meQTLs; 33.9%). As example, in Fig.  6B, the SNP 
rs1130276 had a direct effect both on cg03885332 CpG 
and in CD151 gene expression.
The third most frequent model described G influenc-
ing Me followed by an effect of Me on E levels, with no 
direct relation between G and E, indicating an active 
role for DNA methylation (GMeE model; 2037 meQTLs; 
14.6%). An example of this causal model is shown in 
Fig.  6C where the SNP rs4822458 had a direct effect in 
cg24846343 CpG methylation and this CpG was affecting 
DDTL gene expression.
Finally, the last two causal models were scarcely present 
and involved E having a causal effect in Me. The most fre-
quent among them was the model where G influenced E 
and E influenced Me (GEMe model; 643 meQTLs; 4.6%). 
The other model was the one where G influenced both E 
and Me and, at the same time, E, had a direct relationship 
with Me (GEMe&GMe model; 193 meQTLs; 1.4%). One 
example of GEMe model is shown in Fig. 6D where the 
SNP rs111884657 had a direct effect on gene DNAJC15 
and the gene expression was directly associated with the 
methylation of cg05035143 CpG.
Additional File 9: Table  3 shows how the 52 genes 
in meQTLs are distributed along the different mod-
els. Additional File 10: Fig.  4 shows the distribution 
of CpGs in meQTLs by gene region context along the 
different models. When we considered all CpGs in 
meQTLs (Additional File 10: Fig. 4A), we could see that 
GEMe&GMe model is the one with more proportion of 
CpGs in promoters followed by GMeE and GEMe mod-
els. On the other hand, if we analyzed unique CpGs in 
meQTLs (Additional File 10: Fig. 4B), the proportion of 
CpGs in promoters increased in all the models except 
in GEMe&GMe model. When we analyzed all the SNPs 
(Additional File 10: Fig. 4C) or unique SNPs (Additional 
File 10: Fig.  4D) in meQTLs we could see that, in both 
cases, most of the SNPs were outside the gene associated 
with the meQTL and there were very few SNPs in pro-
moters. We also determined the enrichment of the SNPs 
in haploReg associated with promoter and enhancer-
related chromatin states compared to a subset of ran-
domly sampled SNPs for each model (Additional File 11: 
Table  4). Although we found few statistically significant 
enrichments, probably due to the low number of SNPs 
per chromatin state in each model, a proportion of the 
SNPs were located in predicted enhancers, especially in 
the GMeE&GE, GE&GMe models. The distribution of 
correlation of eQTMs in meQTLs is shown in Additional 
File 12: Fig.  5. If we considered all eQTMs, a positive 
Fig. 4 CpG distribution by gene region context. Proportion of CpGs by gene region context. A 211,268 variable CpGs associated with their nearest 
gene, B 6713 CpGs in mQTLs associated with their nearest gene, C 482 CpGs in eQTMs associated with their nearest gene, D 482 CpGs in eQTMs 
associated with the correlated gene, E 114 CpGs in meQTLs associated with their nearest gene and F 114 CpGs in meQTLs associated with the 
correlated gene
(See figure on next page.)
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Fig. 4 (See legend on previous page.)
Page 8 of 20Díez‑Villanueva et al. Clin Epigenet          (2021) 13:162 
Fig. 5 Boxplot of the correlation between gene and CpG by gene region context. A 557 eQTMs, B 13,987 eQTMs in meQTLs and C 119 unique 
eQTMs in meQTLs
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Table 3 SNPs involved in meQTLs found in the GWAS catalog
GWAS Normal Adjacent Tumor
Traits 1722 48 (3%) 19 (1%) 15 (1%)
SNPs 48,881 64 (0.1%) 26 (0%) 15 (0%)
Age at menopause 84 1 (1%) 1 (1%) 0 (0%)
Alzheimer’s disease (late onset) 55 1 (2%) 1 (2%) 1 (2%)
Asthma 206 2 (1%) 0 (0%) 1 (0%)
Asthma or allergic disease (pleiotropy) 36 1 (3%) 0 (0%) 0 (0%)
Blood metabolite levels 195 1 (1%) 1 (1%) 0 (0%)
Blood protein levels 2772 10 (0%) 7 (0%) 2 (0%)
Blood urea nitrogen levels 111 1 (1%) 0 (0%) 0 (0%)
Childhood ear infection 19 2 (11%) 2 (11%) 2 (11%)
Chronic lymphocytic leukemia 73 1 (1%) 0 (0%) 1 (1%)
Circulating chemerin levels 4 4 (100%) 0 (0%) 0 (0%)
Colorectal cancer 116 3 (3%) 1 (1%) 1 (1%)
Colorectal cancer or advanced adenoma 94 1 (1%) 0 (0%) 0 (0%)
Drug‑induced liver injury (amoxicillin‑clavulanate) 2 1 (50%) 1 (50%) 0 (0%)
Educational attainment (MTAG) 1320 1 (0%) 0 (0%) 0 (0%)
Eosinophil percentage of granulocytes 179 1 (1%) 1 (1%) 1 (1%)
Hair color 449 1 (0%) 0 (0%) 0 (0%)
Heart rate response to exercise 20 1 (5%) 1 (5%) 1 (5%)
Heel bone mineral density 2262 1 (0%) 0 (0%) 0 (0%)
High density lipoprotein cholesterol levels 306 2 (1%) 0 (0%) 0 (0%)
Highest math class taken (MTAG) 1084 1 (0%) 0 (0%) 0 (0%)
Intraocular pressure 512 2 (0%) 0 (0%) 0 (0%)
Liver enzyme levels 9 1 (11%) 0 (0%) 0 (0%)
Liver enzyme levels (gamma‑glutamyl transferase) 26 2 (8%) 2 (8%) 1 (4%)
Lumiracoxib‑related liver injury 1 1 (100%) 0 (0%) 0 (0%)
Mean platelet volume 323 1 (0%) 0 (0%) 0 (0%)
Medication use (adrenergics, inhalants) 55 1 (2%) 0 (0%) 0 (0%)
Menopause (age at onset) 63 1 (2%) 1 (2%) 0 (0%)
Metabolite levels 66 2 (3%) 0 (0%) 0 (0%)
Metabolite levels (small molecules and protein measures) 32 1 (3%) 0 (0%) 0 (0%)
Multiple sclerosis 158 1 (1%) 0 (0%) 0 (0%)
Multiple sclerosis (OCB status) 6 2 (33%) 1 (17%) 1 (17%)
Oligoclonal band status in multiple sclerosis 1 1 (100%) 1 (100%) 1 (100%)
Plasma homocysteine levels (post‑methionine load test) 5 1 (20%) 1 (20%) 0 (0%)
Platelet count 323 1 (0%) 0 (0%) 0 (0%)
Plateletcrit 258 1 (0%) 0 (0%) 0 (0%)
Pulse pressure 747 1 (0%) 0 (0%) 0 (0%)
Red cell distribution width 821 1 (0%) 0 (0%) 0 (0%)
S‑phenylmercapturic acid levels in smokers 1 1 (100%) 0 (0%) 0 (0%)
Serum metabolite levels 76 1 (1%) 1 (1%) 0 (0%)
Systemic lupus erythematosus 195 1 (1%) 1 (1%) 1 (1%)
Systolic blood pressure 1393 1 (0%) 0 (0%) 0 (0%)
Triglyceride levels in current drinkers 39 1 (3%) 0 (0%) 0 (0%)
Triglyceride levels x alcohol consumption (drinkers vs non‑drinkers) interaction 55 1 (2%) 0 (0%) 0 (0%)
Triglyceride levels x alcohol consumption (regular vs non‑regular drinkers) 
interaction
55 1 (2%) 0 (0%) 0 (0%)
Type 1 diabetes 87 1 (1%) 0 (0%) 1 (1%)
Type 2 diabetes 352 1 (0%) 1 (0%) 1 (0%)
Urinary 1,3‑butadiene metabolite levels in smokers 2 2 (100%) 1 (50%) 1 (50%)
White blood cell count 854 2 (0%) 1 (0%) 0 (0%)
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median correlation was found in GMeE and GEMe mod-
els; however, if we considered unique eQTMs, all the 
models had a negative median correlation.
Analysis of tumor tissue
To analyze whether tumor tissue has an altered regula-
tion of gene expression mediated by methylation, we 
performed the mQTL, eQTLs and eQTMs analysis in 95 
paired normal adjacent/tumors samples. In addition to 
the adjustment variables used for normal tissues, tumors 
were also adjusted by stromal content.
Table 1 shows the number of mQTLs, eQTLs, eQTMs 
and meQTLs in Normal, Adjacent and Tumor. We 
found that, with the exception of eQTMs, Normal 
group had a higher number of all the elements when 
compared with Adjacent or Tumor. This is possibly 
due to the larger statistical power of the combination 
of normal samples. Interestingly, Tumor had 3 and 6 
times more eQTMs than Normal and Adjacent, respec-
tively, but fewer other associations, indicating that gene 
expression and DNA methylation changes in tumors 
are highly correlated.
Figure 7 shows the Venn diagrams comparing the three 
groups of samples. All mQTLs, eQTLs and meQTLs had 
most common elements between the three groups of 
samples except the eQTMs of the Tumor group which 
had 74% of specific elements.
Additionally, we examined the overlap of the CpGs 
in mQTLs in Adjacent with those differentially methyl-
ated between normal adjacent tissue and tumor tissue 
found in [8]. We found that only 66 (1.6%) of the CpGs in 
mQTLs were differentially methylated in comparison to 
tumor tissue, as expected since our analysis is centered in 
normal tissues.
Finally, among CpGs and genes involved in eQTMs, 
only 12 (4.7%) of CpGs and 27 (34.6%) of genes were 
differentially methylated and differentially expressed, 
respectively, between tumor tissue and paired adjacent 
normal tissue in the differential analyses previously per-
formed by our group [8].
We also performed the Bayesian network analysis to 
find putative causal relations between triads (Additional 
File 13: Table 5). The proportion of meQTLs in Adjacent 
normal tissue was very similar to the group Normal that 
combined adjacent normal plus healthy mucosae. Like 
Normal and Adjacent, most triads found in Tumors fit-
ted with GMeE&GE model (46.6%) where a SNP affects 
expression directly and indirectly through methylation. 
GE&GMe and GMeE models lose some proportion of 
triads and, in contrast, models where expression explains 
Fig. 6 Examples of the models obtained from the Bayesian networks. First plot shows the diagram of the model and second plot shows the dotplot 
between methylation and gene expression taking genotypes as color legend
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methylation (GEMe&GMe and GEMe models) increased 
their proportion in Tumor.
Discussion
Defining eQTLs, eQTMs, mQTLs and the co-occurring 
triads (meQTLs) in healthy colon tissue can help improve 
our knowledge of how genetic and epigenetic variation 
contribute to gene expression variation, which is impor-
tant to better understand the etiology of colon diseases 
such as colon cancer and the inter-individual differences. 
As in other studies, we have focused on cis analysis as 
the majority of significant correlations have been found 
at less than 1 Mb of distance [7, 34, 35]. Little is known 
about the biological mechanisms that underlie meQTL 
effects. Here we report an approach to find meQTLs and 
explore using Bayesian networks whether the SNPs asso-
ciated with methylation CpGs may have a causal role in 
gene expression changes.
Other studies that have explored the association 
between genetics, methylation and gene expression in 
blood cells also have found that mQTLs are the most 
abundant relationships and eQTMs the least abundant 
[11], suggesting that in colon, DNA methylation variation 
may be a less frequent mechanism than genetic variation 
regarding gene expression variation across individuals. 
Due to the limitation of the number of CpGs included in 
the 450 K array, further analyses using whole-genome or 
reduced-representation bisulfite sequencing should be 
performed to confirm this finding. The involvement of 
DNA methylation in gene expression is highly variable, 
by inhibiting the binding of transcription factors (TFs) 
[12–14], recruiting proteins that silence expression, such 
as methyl-binding proteins or histone deacetylases [15], 
regulating alternative intragenic promoters [16], or being 
influenced by TFs binding [17]. In this regard, Gutier-
rez-Arcelus et al. [11] also showed that the role of DNA 
methylation varied depending on the cell type. Whether 
DNA methylation is a consequence of gene regulation 
and plays a passive role, or whether it regulates gene 
expression and plays an active role, is still far from clear 
[15].
Similarly to other studies [36, 43] the majority of 
eQTMs, both associated and not associated with 
meQTLs, showed the canonical negative correlation 
between gene expression levels and CpG methylation 
levels, and, as expected, all the correlations of the CpGs 
Fig. 7 Common mQTLs, eQTLs, eQTMs and meQTLs between normal tissues and tumor samples. Venn diagrams of Normal tissue (healthy mucosae 
and adjacent normal tissue combined), Adjacent normal tissue alone and Tumor tissue
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within the promoter of the associated gene were nega-
tive. However, a notable proportion of CpGs located in 
the gene body or in intergenic regions showed a positive 
correlation, in line with many studies reporting that the 
function of DNA methylation varies with the genomic 
context [6].
Interestingly, although the CpGs in eQTMs and 
meQTLs were enriched in promoter regions of their clos-
est gene, as a quantitative trait they were associated with 
another gene that was not the closest one, suggesting that 
these regions may act as enhancers regulating the asso-
ciated gene. Another possible explanation would be that 
the methylation of the CpG indeed regulates the closest 
gene, but in a way that the association with gene expres-
sion is weak, but the product of this gene regulates the 
expression with other nearby gene for which we detect a 
stronger association in the eQTM [19, 20].
Most disease-associated SNPs are located in non-cod-
ing regions, and it has been shown for some of them that 
affect regulatory elements [21]. Accordingly, a functional 
analysis of the identified SNPs in meQTLs showed that 
they are enriched in promoter and enhancer chromatin 
states.
Interestingly, the analysis of the GWAS catalog revealed 
circulating chemerin levels function as highly significant. 
Recent works correlate concentration of chemerin with 
risk of colorectal cancer, thus suggesting these meQTLs 
could regulate intestinal homeostasis involved in car-
cinogenesis [22, 23]. Regarding gene functions, the most 
significant ones were those related with metabolism, 
specifically glutathione metabolism. Extensive literature 
links molecules in these pathways with colon carcinogen-
esis [49, 50]. Also, three meQTLs have been identified in 
colorectal cancer GWAS: rs9271770 related with HLA-
DQA1 [26], rs3087967 related with C11orf53 [26] and 
rs3802842 [27] intronic to COLCA1 and COLCA2 genes. 
The last two SNPs are located near each other in chromo-
some 11 and may not be completely independent because 
they share the same CpG cg23091777.
The number of mQTLs, eQTLs and meQTLs were 
lower when analyzed in tumors than their paired normal 
tissue, indicating a general deregulation of gene expres-
sion and methylation. The number of eQTMs, however, 
was larger in tumors and these eQTMs were specific for 
tumoral tissue, indicating that epigenetic but not genetic 
variation is an important factor driving gene expression 
variation in colon tumors in contrast to what occurs in 
normal colon tissue. This could be in part related to large 
chromosomal aberrations with copy number changes 
that might impact simultaneously methylation and gene 
expression.
Only a very small proportion of the CpGs involved in 
the mQTLs and eQTMs, 1.6% and 4.7%, respectively, 
are differentially methylated between Tumor and Adja-
cent normal, suggesting that the CpGs related to genetic 
and gene expression inter-individual variability in nor-
mal colon tissue are not directly involved in the colon 
tumorigenesis process. In contrast, the 34.6% of the 
genes involved in the eQTMs are differentially expressed 
between Tumor and Adjacent normal. However, the 
CpGs of the associated eQTMs are not differentially 
methylated between Tumor and Adjacent normal, sug-
gesting that the mechanism underlying the altered 
expression of these genes in tumors is not DNA methyla-
tion, or at least it is not related to these CpGs.
In order to better understand the functional rela-
tionships between genetic variation, methylation and 
gene expression, we have used Bayesian networks. We 
assumed that the genetic component in these models 
(SNP) was driving the association with methylation and 
gene expression, and that the relationship between the 
latter two could be in either direction. Interestingly, we 
found that the most common causal relationship model 
was that in which the SNP affects expression both directly 
and indirectly through methylation (GMeE&GE model), 
followed by the model where the SNP affects methylation 
and expression independently of one another, thus DNA 
methylation having a passive role (GE&GMe model). This 
second model was also often found in fibroblasts and 
lymphoblastoid cell lines [11]. It is noteworthy that in 
both models there is a direct effect of the SNP on gene 
expression, reinforcing the predominant role of genetic 
variation on the inter-individual expression variability. 
The third most common causal relationship model was 
the mediation of DNA methylation (GMeE model), in 
which the SNP affects DNA methylation and DNA meth-
ylation in turn affects gene expression. This model was 
also observed in the analysis of T-cells [11]. The CpGs 
involved in these models show mainly a negative corre-
lation with expression, which could be explained by the 
inhibition of TF binding or the recruitment of repres-
sive proteins to regulatory elements by DNA methyla-
tion. Alternatively, DNA methylation can also create new 
binding sites for TF [28].
The models where the SNP affects methylation medi-
ated by expression (GEMe and GEMe&GMe) are less 
frequent. The underlying mechanism may involve TFs 
whose binding to promoters would influence methylation 
so that when there is no binding DNA is accessible to be 
methylated [17]. Accordingly, these models are enriched 
in CpGs located in promoters. Interestingly, if we analyze 
the correlation between gene expression and methyla-
tion, considering the unique CpG-gene pairs in meQTLs, 
all models have a negative correlation.
Our analysis did not identify models in which DNA 
methylation and gene expression were unrelated to SNPs, 
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showing other indirect associations. Though some of 
these relationships might exist in reality, probably we did 
not observe them because our analysis was restricted to 
QTLs.
Study limitations
We have restricted our analysis to cis-associations, 
though there might be other significant eQTLs, eQTMs 
and mQTLs in trans. Though it has been reported in 
other tissues that long-distance relationships between 
SNPs, CpGs and genes exist [29], the biological interpre-
tation would be difficult and probably most of those asso-
ciations would be indirect effects.
Though there is high correlation in methylation among 
CpGs in islands, we opted to study associations at indi-
vidual CpG level instead of at island level. This was 
because some studies have proven that a single differen-
tially methylated CpG could affect gene expression [30]. 
To avoid inflating the number of findings due to redun-
dancy, we identified blocks of contiguous correlated 
CpGs. Though some of these blocks are isolated CpGs in 
islands associated with gene expression, these findings, 
would require additional validation.
To ensure a robust analysis, we have been very strict 
both in the filters to include SNPs, CpGs or genes and 
in the p-value threshold to classify an eQTL, eQTM or 
mQTL as significant. If we compare our methodology 
with the one used in other papers, the list of significant 
eQTLs, eQTMs and mQTLs is smaller in our analy-
sis and this may have made us discard some interesting 
results. The sample size of our study was limited, and we 
could not find other colon tissue datasets to validate the 
results or meta-analyze them.
Finally, it is well known that most DNA methylation 
variability is not genetically influenced, but related to 
environmental exposures such as smoking, diet or sim-
ply ageing. In fact, recent studies have identified signa-
tures of CpGs whose global methylation status measures 
chronological age, known as the DNA methylation clock 
[31]. Thus, DNA methylation of eQTMs and mQTLs may 
vary with age affecting the interactions of DNA methyla-
tion with SNPs and gene expression.
Conclusions
We have generated a comprehensive resource of DNA 
methylation variants in colon tissue which has allowed 
us to gain insight into the role of epigenetic variation in 
the interplay between genetic and gene expression varia-
tion. Results have shown a complex scenario in which the 
canonical relationship based on the influence of genetic 
variation on DNA methylation which in turn affects gene 
expression is not the unique, but DNA methylation can 
participate both in a passive and in an active manner. 
However, the factors determining the nature of this rela-
tionship are unknown, but they may be a combination of 




The aim of this study is to map genetic variation affecting 
methylation patterns (mQTLs) and methylation CpGs 
affecting gene expression (eQTMs) in healthy colon tis-
sue. Using these two list of quantitative traits and the 
already published list of eQTLs [7], identify co-localizing 
triads of genetic variants, methylation sites and genes 
(meQTLs) and find causal relations between the elements 
in meQTLs using Bayesian networks.
Colon tissue samples
Fresh tumor and paired adjacent normal mucosa sam-
ples of one hundred patients of colorectal cancer and 
fifty Healthy mucosa donors were included in the analy-
sis. Sample recruiting and clinical characteristics of the 
samples can be found in [8, 32] but shortly, Healthy indi-
viduals had a mean age of 63  years while patients were 
71  years old in mean. Half of the Healthy individuals 
were females, but only 28% among patients. All the colon 
cancer patients were diagnosed in stage II, received only 
radical surgery as treatment and tumors were microsat-
ellite stable. Additional information about the study and 
patient samples can be found at [33].
Genotyping data
Genotypes were obtained hybridizing genomic DNA 
extracted from colonic mucosa in Affymetrix Genome-
Wide Human SNP 6.0 array (Affymetrix, Santa Clara, 
USA), which includes near 1 million single nucleotide 
polymorphism (SNP) markers. Genotype calling was per-
formed with Corrected Robust Linear Model with Maxi-
mum Likelihood Classification (CRLMM) algorithm as 
implemented in R/Bioconductor package crlmm [34].
Whole genome imputation was performed using the 
IMPUTE2 software package [35] after haplotyping with 
SHAPEIT2 [36]. The 1000 genomes panel for CEU popu-
lation, March 2012 version, was used as reference panel. 
We accounted for genotype imputation uncertainties by 
using an allelic dosage model. After imputation, SNPs 
were filtered out if the imputation quality info index was 
less than 0.4, the certainty index was less than 0.9 and the 
minor allele frequency (MAF) was less than 0.05. SNPs 
with more than 10% of missing data were also filtered out 
and only SNPs in autosomal chromosomes were consid-
ered. A total of 6,568,592 SNPs were included in the anal-
ysis. A total of 4 samples were excluded due to quality or 
sex concordance problems (3 Healthy and 1 Adjacent) so 
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146 samples (47 Healthy and 99 Adjacent) remained for 
the analysis.
DNA methylation data
DNA methylation levels and differential methylation 
between samples (Tumor vs Adjacent and Adjacent vs 
Healthy) were previously assessed by our group [8]. In 
brief, DNA was extracted from colon mucosa specimens 
using the phenol–chloroform protocol. The extracted 
DNA was quantified using a Nano Drop ND 2000c spec-
trophotometer (NanoDrop Thermo scientific, Wilming-
ton, DE) and stored at 4ºC. Bisulfite conversion of 600 ng 
of DNA was performed according to the manufacturer’s 
recommendations for the Illumina Infinium Assay (EZ 
DNA methylation kit. Zymo Research. Cat. No. D5004). 
The incubation profile was 16 cycles at 95ºC for 30  s, 
50ºC for 60 min and a final holding step at 4ºC [37].
DNA methylation profiles were generated from the 
Illumina Human Methylation 450  K BeadChip assay. 
Technical details of this array are described elsewhere 
[38, 39]. This array interrogates methylation levels of 
485,577 CpG sites. Array data were processed follow-
ing a pipeline within the Bioconductor R environment. 
Library minfi was used for quality control and normali-
zation [40]. Sample concordance was checked verifying 
the SNPs of the 450 K array with those of the Affymetrix 
Genome-Wide Human SNP 6.0 array (Affymetrix, Santa 
Clara, USA). Samples from 100 cancer patients and 39 
Healthy donors were processed and after array quality 
control, six low-quality samples were excluded (2 Healthy 
and 4 patients), thus the final dataset analyzed contained 
data from 229 samples (37 Healthy, 96 Adjacent and 96 
Tumor).
High-quality methylation probes were selected for 
analysis. Probes were excluded when signal detection 
p-value was > 0.01 for more than 5% of the samples. We 
discarded 41,082 probes that ambiguously mapped to 
multiple locations in the human genome with up to two 
mismatches [41]. We excluded 11,854 probes that con-
tained SNPs within 10 bp. This resulted in a final set of 
430,086 probes. We mapped the probe locations to the 
human genome sequence using UCSC genome browser 
(hg19) to retrieve an updated annotation of all genes. 
For the selected probes, a subset-quantile within array 
normalization (SWAN) was used to reduce systematic 
sources of bias known for this array [42].
At each CpG site, the methylation level was estimated 
as a β-value, which is the ratio of intensity signal obtained 
from the methylated allele over the sum of methylated 
and unmethylated alleles. M-values, the logit transfor-
mation of β-values, were used for the analysis, which 
increases the range of values in the extremes and reduces 
the dependency between mean and variance [43]. Probes 
outside autosomal chromosomes and with low variabil-
ity were removed. Also, low variability probes were fil-
tered. For that, a parametric-mixture cluster analysis on 
the standard deviation (sd) was used, and probes in the 
low variability clusters (sd < 0.05) were excluded (final 
n = 211,268, Additional file  14: Fig.  6). We used the sd 
and not the coefficient of variation (sd/mean) because 
that increased the apparent variability of very low meth-
ylated probes, which probably do not have a biological 
significance and would increase the likelihood of finding 
spurious associations [44].
Since principal component analyses revealed that adja-
cent normal mucosa samples clustered with samples 
from healthy individuals [8], adjacent normal and healthy 
mucosa samples were analyzed together in subsequent 
analyses (Normal).
Gene expression data
Affymetrix Human Genome U219 Array Plate platform 
(Affymetrix, Santa Clara, CA, USA) was used to obtain 
gene expression data. Details are explained in [8], briefly, 
a block experimental design was performed to three 
96-array plates to avoid batch effects. Robust Multiar-
ray Average algorithm in affy package from R [45] was 
used to normalize data. After quality control 246 sam-
ples remain for the analysis (50 M, 98 N and 98 T). Genes 
with very low variability (standard deviation < 0.1 among 
all samples) and outside autosomal chromosomes were 
filtered out. A total of 14,654 genes remained in the 
analysis.
Methylation quantitative trait loci
After quality control and considering only common 
samples between genotyping and methylation, a total of 
132 samples (37 Healthy and 95 Adjacent) were used to 
identify mQTLs (Additional File 1: Fig. 1). To identify cis-
mQTLs, each methylation CpG was correlated with SNPs 
within 1 Mb upstream and downstream methylation site 
(2  Mb overall). The genetic association was tested in a 
linear additive model (genotype dose vs methylation 
M-value) using the function modelLINEAR in R pack-
age MatrixEQTL [46] adjusting for age, colon tissue site 
(right/left) and gender. We used a p-value threshold of 
4.9e−11 (0.05/211,268 CpGs × 4817 SNPs). The number 
of SNPs was calculated as the median of SNPs at a maxi-
mum distance of 1 Mb for each CpG  (Fig. 1).
Independent mQTLs were calculated. First, blocks of 
correlated (r2 > 0.3) cis-CpGs were created and mQTLs 
were defined by these CpG blocks. After that, blocks of 
correlated (r2 > 0.3) cis-SNPs were created and mQTLs 
blocks were redefined based on these SNP blocks. For 
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each mQTL block based on independent CpGs and 
SNPs, we choose the one with the minimum p-value as 
the representative mQTL of the block.
Gene expression quantitative trait loci
In this analysis, we used 30,125 eQTLs found in this sam-
ple collection and reported in Moreno et al. [7]. Briefly, 
144 samples (47 Healthy and 97 Adjacent) (Additional 
File 1: Fig.  1) were used and eQTLs were identified 
within a maximum distance of 1  Mb of the gene TSS 
(cis-eQTLs). A p-value threshold of 6.8e−10 (0.05/14,654 
genes × 5000 SNPs) was applied. The number of SNPs 
was calculated as the median number of SNPs at a maxi-
mum distance of 1 Mb for each gene (Fig. 1).
Independent eQTLs were calculated. For each gene, 
blocks of correlated (r2 > 0.3) cis-SNPs were created and 
eQTLs were defined by these SNP blocks. For each eQTL 
block based on independent SNPs, we choose the one 
with the minimum p-value as the representative eQTL of 
the block.
Gene expression quantitative trait methylation site
131 Normal samples (37 Healthy and 94 Adjacent) 
between gene expression and methylation were used 
to find the eQTMs performing the same analysis as for 
finding mQTLs (Additional File 1: Fig.  1). In the case 
of eQTMs, the association between methylation levels 
(M-value) and gene expression was tested adjusting by 
age, colon tissue site (right/left), tissue type (Healthy/
Adjacent) and gender. A p-value threshold of 1.7e−08 
(0.05/14,654 genes × 201 CpGs) was used. The number of 
CpGs was calculated as the median of CpGs at a maxi-
mum distance of 1 Mb for each gene (Fig. 1).
Independent eQTMs were calculated. For each gene, 
blocks of correlated (r2 > 0.3) cis-CpGs were created and 
eQTMs were defined by these CpG blocks. For each 
eQTM block based on independent CpGs, we choose 
the one with the minimum p-value as the representative 
eQTM of the block.
Co‑occurring triads of associated genetic variants, 
methylation sites and gene expression levels
To find co-regulation of methylation and expression lev-
els by the same genetic variants (meQTLs), we searched 
for common SNPs among mQTLs and eQTLs, and then, 
we identified overlapping eQTMs (Fig. 1).
The number of independent meQTLs was calculated. 
For each gene, blocks of correlated (r2 > 0.3) cis-CpGs 
were created and meQTLs were defined by these CpG 
blocks. After that, blocks of correlated (r2 > 0.3) cis-SNPs 
were created and meQTLs blocks were redefined based 
on these SNP blocks. Finally, we count the number of 
meQTL blocks based on independent CpGs and SNPs for 
each gene.
Functional annotation and pathway analysis
To annotate SNPs, the R package haploR [47] was used 
to query the HaploReg database [48]. HaploReg includes 
different types of annotation sources such as mamma-
lian conserved regions (GERP and SiPhy algorithms), 
epigenetic marks (chromatin states (ChromHMM) cor-
responding to promoter or enhancer elements, specific 
promoter and enhancer histone marks) and eQTLs, 
for different cell and tissue types; in particular, we used 
data from colonic mucosa. We also submitted a random 
list of 150,000 cis-SNPs (within 1 Mb of gene TSS) that 
was used to calculate the expected distributions of each 
annotation. These were compared to the results of the 
meQTLs using a Fisher exact test. Bonferroni adjusted 
p-values were calculated for chromatin states and histone 
marks separately.
The R package enrichR [49, 50] was used to analyze for 
enrichment of the sets of genes tagged by meQTLs in dif-
ferent databases including KEGG [51], Reactome [52], 
GO [53] and MSigDB [54, 55].
Enrichment in genome‑wide association studies
We assessed whether the identified SNPs were associated 
with complex traits and diseases in European genome-
wide association studies (GWAS) results from the GWAS 
catalog [56] using the MRInstruments package from R 
[57]. SNPs with a p-value greater than 5e−8 were filtered 
out from the catalog.
Causal relations of meQTLs triads
Hill-climbing algorithm in bnlearn package from R 
[58] has been used to build a Bayesian network for each 
meQTLs triad. For that, M-values of methylation data, 
SNP dosage data and expression data were used. Blacklist 
parameter of the algorithm was used to avoid including 
the causal relation arcs where gene expression or CpG 
methylation explained the genetics of the SNP. The pos-
terior probabilities for each potential causal model given 
by the Bayesian network analysis will allow us to identify 
the most probable causal relation in each meQTLs triad 
between the genetic variant, the methylation CpG and 
the levels of gene expression.
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Additional file 1: Figure 1. Number of samples in each data type and 
each quantitative trait analysis.
Additional file 2: Data 1. List of independent mQTLs.
Additional file 3: Table 1. For each chromosome, the number of ele‑
ments (genes, CpGs and SNPs) analyzed, columns 1 to 3, and for each 
list of mQTLs, eQTMs, eQTLs and meQTLs, the number of elements, the 
number of unique elements and the number of non‑correlated elements. 
Non correlated elements must be in cis and  r2>0.3, see methods
Additional file 4: Figure 2. CpG distribution by CpG island context. Pro‑
portion of CpGs by CpG island context. A) 211,268 variable CpGs, B) 6,713 
CpGs in mQTLs, C) 482 CpGs in eQTMs, D) 114 CpGs in meQTLs.
Additional file 5: Data 2. List of independent eQTMs.
Additional file 6: Data 3. List of independent eQTLs
Additional file 7: Figure 3. Proportion difference between random SNPs 
and SNPs in meQTLs in the Normal group for the different chromatin 
states. (*) indicates a significant enrichment or underrepresentation. X axis 
is: 1_TssA ‑ Active transcription start site; 2_PromU ‑ Promoter upstream 
transcription start site; 3_PromD1 ‑ Promoter downstream transcrip‑
tion start site 1; 4_PromD2 ‑ Promoter downstream transcription start 
site 2; 22_PromP ‑ Poised promoter; 23_PromBiv ‑ Bivalent promoter; 
10_TxEnh5 ‑ Transcribed 5′preferential and enhancer; 11_TxEnh3 ‑ Tran‑
scribed 3′preferential and enhancer; 12_TxEnhW ‑ Transcribed and weak 
enhancer; 13_EnhA1 ‑ Active enhancer 1; 14_EnhA2 ‑ Active enhancer 
2; 15_EnhAF ‑ Active enhancer flank; 16_EnhW1 ‑ Weak enhancer 1; 
17_EnhW2 ‑ Weak enhancer 2; 18_EnhAc ‑ Primary H3K27ac–possible 
enhancer; 9_TxReg ‑ Transcribed and regulatory; 19_Dnase ‑ Primary 
DNase.
Additional file 8: Table 2. meQTLs functional analysis obtained with 
enrichR R package. Enrichment analysis of KEGG, GO and Reactome 
databases. For each term of the data base, the number of genes found in 
meQTLs/number of genes associated to the term (Overlap), the propor‑
tion test p‑value, adjusted p‑value and combined score and the genes in 
meQTLs that are included in the list of genes associated to the term.
Additional file 9: Table 3. Distribution of the 52 genes in meQTLs by each 
causal model.
Additional file 10: Figure 4: A) Proportion of CpGs, B) unique CpGs, C) 
SNPs and D) unique SNPs in meQTLs in the Normal group by gene region 
context along the different models.
Additional file 11: Table 4. haploReg results by model. Fisher exact 
test comparing, for chromatin states and histone marks annotation in hap‑
loReg database, the proportion of SNPs in each model with a sample of 
cis‑SNPs. Bonferroni adjusted p‑value was calculated for chromatin states 
and histone marks separately.
Additional file 12: Figure 5: Distribution of the correlation between 
CpGs and genes (eQTMs) in meQTLs (top) and unique eQTMs in meQTLs 
(bottom) for the Normal group along the different models.
Additional file 13: Table 5. Comparison of models produced with Bayes‑
ian networks between the three groups of samples (Normal, Adjacent and 
Tumor). For each group, the number of meQTLs, CpGs, SNPs and genes in 
each model.
Additional file 14: Figure 6. A) Mixture of normal distributions and clus‑
ters of CpGs according to the standard deviation (sd) of the beta‑values. 
B) Distribution of CpGs according to the mean beta‑value and standard 
deviation, with clusters colored. CpGs with sd < 0.05 were excluded from 
analysis.
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